Compare LOCO & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCO | OLMA |
|---|---|---|
| Founded | 1980 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 501.3M | 994.9M |
| IPO Year | 2014 | 2020 |
| Metric | LOCO | OLMA |
|---|---|---|
| Price | $16.39 | $11.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $14.17 | ★ $44.89 |
| AVG Volume (30 Days) | 194.6K | ★ 891.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.65 | ★ 15.00 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $401,701,000.00 | N/A |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $3.98 | N/A |
| P/E Ratio | $60.63 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $8.99 | $4.47 |
| 52 Week High | $17.40 | $36.26 |
| Indicator | LOCO | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.